Literature DB >> 29331267

Identification and initial optimization of inhibitors of Clostridium difficile (C. difficile) toxin B (TcdB).

Jeffrey J Letourneau1, Ilana L Stroke2, David W Hilbert3, Laurie J Sturzenbecker2, Brett A Marinelli2, Jorge G Quintero2, Joan Sabalski2, Linh Ma2, David J Diller2, Philip D Stein2, Maria L Webb2.   

Abstract

The discovery, synthesis and preliminary structure-activity relationship (SAR) of a novel class of inhibitors of Clostridium difficile (C. difficile) toxin B (TcdB) is described. A high throughput screening (HTS) campaign resulted in the identification of moderately active screening hits 1-5 the most potent of which was compound 1 (IC50 = 0.77 µM). In silico docking of an early analog offered suggestions for structural modification which resulted in the design and synthesis of highly potent analogs 13j(IC50 = 1 nM) and 13 l(IC50 = 7 nM) which were chosen as leads for further optimization.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Benzodiazepinedione; Clostridium difficile; Inhibitor; TcdB; Toxin

Mesh:

Substances:

Year:  2018        PMID: 29331267     DOI: 10.1016/j.bmcl.2018.01.005

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  3 in total

1.  Treatment of Clostridium difficile Infection with a Small-Molecule Inhibitor of Toxin UDP-Glucose Hydrolysis Activity.

Authors:  Ilana L Stroke; Jeffrey J Letourneau; Teresa E Miller; Yan Xu; Igor Pechik; Diana R Savoly; Linh Ma; Laurie J Sturzenbecker; Joan Sabalski; Philip D Stein; Maria L Webb; David W Hilbert
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

2.  Recent advances in the treatment of C. difficile using biotherapeutic agents.

Authors:  Vo Van Giau; Hyon Lee; Seong Soo A An; John Hulme
Journal:  Infect Drug Resist       Date:  2019-06-10       Impact factor: 4.003

Review 3.  Exotoxin-Targeted Drug Modalities as Antibiotic Alternatives.

Authors:  Moona Sakari; Arttu Laisi; Arto T Pulliainen
Journal:  ACS Infect Dis       Date:  2022-01-31       Impact factor: 5.084

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.